



CLAIMS

1. A crystalline free base of a compound of formula:




having an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about $19.5^\circ 2\theta$.

2. A crystalline free base of a compound of formula:



having an XRPD pattern comprising characteristic peaks at about 9.1 and $19.5^\circ 2\theta$.


3. A crystalline free base of a compound of formula:



having an XRPD pattern comprising characteristic peaks at about 9.1 , 15.4 , 19.5 and


21.4° 2 θ .

4. A crystalline free base of a compound of formula:



having one or more XRPD 2 θ -reflections (°) selected from the group consisting of about 9.1, 12.5, 15.2, 15.4, 19.2, 19.5, 20.3, 20.5, 21.4, 21.7, 21.9, 23.1, 23.3, 23.6, and 24.3.

5. A crystalline free base of a compound of formula:



having an XRPD pattern substantially as shown in FIG. 1.

6. A crystalline free base 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having a Fourier transform infrared spectroscopy (FT-IR) spectrum comprising one or more peaks at about 1603, 1533, 1487, 1080, 857, and 681 cm⁻¹.

7. A crystalline free base 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having an FT-IR spectrum substantially as shown in FIG. 2.
8. A crystalline free base 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having (i) an XRPD pattern comprising one or more peaks at about 9.1, 15.4, 19.5 and 21.4° 2 θ ; and (ii) a FT-IR spectrum comprising one or more peaks at about 1603, 1533, 1487, 1080, 857, and 681 cm⁻¹.
9. A crystalline free base 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having a DSC thermogram with an endotherm having an onset temperature of approximately 184°C.
10. A crystalline free base 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having a DSC thermogram substantially as shown in FIG. 3.
11. A pharmaceutical composition comprising a crystalline compound according to any one of claims 1-10.
12. Use of a crystalline compound according to any one of claims 1-10 in the manufacture of a medicament for the treatment of a cancer in a subject in need thereof.
13. The use according to claim 12, wherein the subject is a mammal.
14. The use according to claim 13, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.
15. The use according to claim 13, wherein the mammal is a human.

16. The use according to claim 12 wherein at least one additional anti-cancer agent is to be administered to the subject.

17. Use of a crystalline compound according to any one of claims 1-10 in the manufacture of the pharmaceutical composition according to claim 11 for the treatment of a cancer in a subject in need thereof.


18. The use according to claim 17, wherein the subject is a mammal.

19. The use according to claim 18, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.

20. The use according to claim 18, wherein the mammal is a human.


21. The use according to claim 17, wherein at least one additional anti-cancer agent is to be administered to the subject.

22. A crystalline hydrochloride salt of a compound of formula:




having an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about $6.7^{\circ} 2\theta$.

23. A crystalline hydrochloride salt of a compound of formula:




having an XRPD pattern comprising characteristic peaks at about 6.7 and 11.0° 2 θ .

24. A crystalline hydrochloride salt of a compound of formula:




having an XRPD pattern comprising characteristic peaks at about 6.7, 11.0, 17.6 and 19.9° 2 θ .

25. A crystalline hydrochloride salt of a compound of formula:



having one or more XRPD 2 θ -reflections (°) selected from the group consisting of about 6.1, 6.7, 11.0, 12.1, 13.7, 15.2, 16.5, 17.6, 17.9, 18.4, 18.7, 19.6, 19.9, and 20.4.

26. A crystalline hydrochloride salt of a compound of formula:



having an XRPD pattern substantially as shown in FIG. 4.

27. A form C crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having a Fourier transform infrared spectroscopy (FT-IR) spectrum comprising one or more peaks at about 1610, 1523, 1219, 1141, 1076, and 845 cm^{-1} .

28. A form C crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having an FT-IR spectrum substantially as shown in FIG. 5.

29. A form C crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having (i) an XRPD pattern comprising one or more peaks at about 6.7, 11.0, 17.6, and 19.9° 2θ ; and (ii) a FT-IR spectrum comprising one or more peaks at about 1610, 1523, 1219, 1141, 1076, and 845 cm^{-1} .

30. A form C crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having a DSC thermogram with an endotherm having an onset temperature of approximately 239°C.

31. A form C crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide mono HCl having a DSC thermogram substantially as shown in FIG. 6.

32. A pharmaceutical composition comprising a crystalline compound according to any one of claims 22-31.

33. Use of a crystalline compound according to any one of claims 22-31 in the manufacture of a medicament for the treatment of a cancer in a subject in need thereof.

34. The use according to claim 33, wherein the subject is a mammal.

35. The use according to claim 34, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.

36. The use according to claim 34, wherein the mammal is a human.

37. The use according to claim 33 wherein at least one additional anti-cancer agent is to be administered to the subject.

38. Use of a pharmaceutical composition according to claim in the manufacture of the pharmaceutical composition according to claim 32 for the treatment of a cancer in a subject in need thereof.


39. The use according to claim 38, wherein the subject is a mammal.

40. The use according to claim 39, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.

41. The use according to claim 39, wherein the mammal is a human.


42. The use according to claim 38, wherein at least one additional anti-cancer agent is to be administered to the subject.

43. A crystalline hydrochloride salt of a compound of formula:




having an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about $10.5^\circ 2\theta$.

44. A crystalline hydrochloride salt of a compound of formula:




having an XRPD pattern comprising characteristic peaks at about 6.2 and $10.5^\circ 2\theta$.

45. A crystalline hydrochloride salt of a compound of formula:




having an XRPD pattern comprising characteristic peaks at about 6.2 , 10.5 , 22.4 and $28.5^\circ 2\theta$.

46. A crystalline hydrochloride salt of a compound of formula:



having one or more XRPD 2θ -reflections ($^{\circ}$) selected from the group consisting of about 5.8, 5.9, 6.2, 10.5, 11.8, 12.4, 15.9, 17.6, 17.8, 20.0, 20.4, 21.1, 21.4, 21.9, 22.4, 23.1, 24.0, 24.2, 24.9, and 25.3.

47. A crystalline hydrochloride salt of a compound of formula:



having an XRPD pattern substantially as shown in FIG. 7.

48. A form A crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl hydrate having a Fourier transform infrared spectroscopy (FT-IR) spectrum comprising one or more peaks at about 1573, 1237, 1163, 946, and 790 cm^{-1} .

49. A form A crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl hydrate having an FT-IR spectrum substantially as shown in FIG. 8.

50. A form A crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl hydrate having (i) an XRPD pattern comprising one or more peaks at about 6.2, 10.5, 22.4, and 28.5° 2 θ ; and (ii) a FT-IR spectrum comprising one or more peaks at about 1573, 1237, 1163, 946, and 790 cm⁻¹.

51. A form A crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl hydrate having a DSC thermogram substantially as shown in FIG. 9.

52. A pharmaceutical composition comprising a crystalline compound according to any one of claims 43-51.

53. Use of a crystalline compound according to any one of claims 43-51 in the manufacture of a medicament for the treatment of a cancer in a subject in need thereof.

54. The use according to claim 53, wherein the subject is a mammal.

55. The use according to claim 54, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.

56. The use according to claim 54, wherein the mammal is a human.

57. The use according to claim 53, wherein at least one additional anti-cancer agent is to be administered to the subject.

58. Use of a crystalline compound according to any one of claims 43-51 in the manufacture of the pharmaceutical composition according to claim 52 for the treatment of a cancer in a subject in need thereof.


59. The use according to claim 58, wherein the subject is a mammal.

60. The use according to claim 59, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.

61. The use according to claim 59, wherein the mammal is a human.


62. The use according to claim 58, wherein at least one additional anti-cancer agent is to be administered to the subject.

63. A crystalline hydrochloride salt of a compound of formula:




having an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about $10.7^{\circ} 2\theta$.

64. A crystalline hydrochloride salt of a compound of formula:




having an XRPD pattern comprising characteristic peaks at about 10.7 and $18.1^{\circ} 2\theta$.

65. A crystalline hydrochloride salt of a compound of formula:




having an XRPD pattern comprising characteristic peaks at about 6.0, 10.7, 12.7, and 18.1° 2 θ .

66. A crystalline hydrochloride salt of a compound of formula:



having one or more XRPD 2 θ -reflections (°) selected from the group consisting of about 6.0, 6.3, 10.7, 12.0, 12.7, 15.6, 16.2, 16.3, 16.7, 17.9, 18.1, and 21.4.

67. A crystalline hydrochloride salt of a compound of formula:



having an XRPD pattern substantially as shown in FIG. 10.

68. A form D crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl having a Fourier transform infrared spectroscopy (FT-IR) spectrum comprising one or more peaks at about 1537, 1471, 1239, 1163, 1067, and 946 cm^{-1} .

69. A form D crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl having an FT-IR spectrum substantially as shown in FIG. 11.

70. A form D crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl having (i) an XRPD pattern comprising one or more peaks at about 6.0, 12.7, and 18.1° 2 θ ; and (ii) a FT-IR spectrum comprising one or more peaks at about 1537, 1471, 1239, 1163, 1067, and 946 cm^{-1} .

71. A form D crystalline 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide HCl having a DSC thermogram substantially as shown in FIG. 12.

72. A pharmaceutical composition comprising a crystalline compound according to any one of claims 63-71.

73. Use of a crystalline compound according to any one of claims 63-71 in the manufacture of a medicament for the treatment of a cancer in a subject in need thereof.

74. The use according to claim 73, wherein the subject is a mammal.

75. The use according to claim 74, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.

76. The use according to claim 74, wherein the mammal is a human.

77. The use according to claim 73, wherein f at least one additional anti-cancer agent is to be administered to the subject.

78. Use of a crystalline compound according to any one of claims 63-71 in the manufacture of the pharmaceutical composition according to claim 72 for the treatment of a cancer in a subject in need thereof.

79. The use according to claim 78, wherein the subject is a mammal.

80. The use according to claim 79, wherein the mammal is selected from the group consisting of humans, primates, farm animals, and domestic animals.

81. The use according to claim 79, wherein the mammal is a human.

82. The use according to claim 78, wherein at least one additional anti-cancer agent is to be administered to the subject.

83. A crystalline compound according to any one of claims 1-10 for use in the treatment of a cancer in a subject in need thereof.

84. A pharmaceutical composition comprising a crystalline compound according to any one of claims 1-10 for use in the treatment of a cancer in a subject in need thereof.

85. A crystalline compound according to any one of claims 22-31 for use in the treatment of a cancer in a subject in need thereof.

86. A pharmaceutical composition comprising a crystalline compound according to any one of claims 22-31 for use in the treatment of a cancer in a subject in need thereof.

87. A crystalline compound according to any one of claims 43-51 for use in the treatment of a cancer in a subject in need thereof.

88. A pharmaceutical composition comprising a crystalline compound according to any one of claims 43-51 for use in the treatment of a cancer in a subject in need thereof.

89. A crystalline compound according to any one of claims 63-71 for use in the treatment of cancer in a subject in need thereof.

90. A pharmaceutical composition comprising a crystalline compound according to any one of claims 63-71 for use in the treatment of a cancer in a subject in need thereof.